New drug combo shows promise for lung cancer brain metastases
NCT ID NCT02971501
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 5 times
Summary
This phase II trial tested whether adding bevacizumab to osimertinib works better than osimertinib alone for patients with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. Only 5 patients were enrolled. The goal was to see if the combination could delay cancer progression and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib and bevacizumab
- What this could lead to
- If successful, this could point toward a more effective treatment for lung cancer that has spread to the brain, potentially improving how long patients live without the disease getting worse.
- What could go wrong
- This is a very small, early-phase trial with only 5 participants, so results may not apply to all patients. The study was terminated early, making it hard to draw firm conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Keck Medical Center of USC Pasadena
Pasadena, California, 91105, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Moffitt Cancer Center-International Plaza
Tampa, Florida, 33607, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Nebraska Medicine-Bellevue
Bellevue, Nebraska, 68123, United States
-
Nebraska Medicine-Village Pointe
Omaha, Nebraska, 68118, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New drug combo shows promise for tough cancers
- Brain zap study: will precision radiation save your memory?